Hypertriglyceridemia: Targeted Therapies and Updated Indications-Icosapent Ethyl, Volanesorsen
Statins remain the first-choice drugs to reduce CV risk for those with high triglycerides.
Icosapent ethyl (2 g twice daily) is now uniquely recommended—when added to statin—in high or very high risk patients if TG 135–499 mg/dL persists, based on REDUCE-IT results (Class IIa, Level B).16